What Redwood AI does

Redwood AI Corp. (CSE: AIRX; OTCQB: RDWCF; FSE: Y0N) is a Vancouver-based, publicly listed artificial intelligence company that develops and commercializes Reactosphere, a proprietary AI-powered chemistry platform. Originally incorporated as Marshall Technologies Corp., the company completed its public listing on the Canadian Securities Exchange on February 6, 2026, rebranded its core platform from SythesAltzer to Reactosphere in March 2026, and operates today with a small core team of 1–10 employees. Reactosphere combines proprietary generative foundation models with deep chemistry expertise to support synthesis planning, reaction optimization, molecular design, chemical risk assessment, and vendor intelligence, targeting pharmaceutical and biotechnology companies, defense and public safety organizations, industrial chemical firms, and academic research institutions.

The platform's technology stack is anchored by a model trained on more than 21 million chemical reaction examples (expanded approximately 5x from around 4 million through a collaboration with UBC Professor Jolene Reid), with modular components that include an Optimization Module based on Bayesian optimization and experimental design, a Chemical Pricing and Availability System monitoring 90+ global vendors, a Chemical Risk Assessment Module for hazardous material screening, and Q-SAFE for quantum-enhanced hazardous chemical classification. The system runs as a production cloud deployment with role-based access controls and supports CPU-only and air-gapped operation, allowing it to serve enterprise and defense clients with stringent data sovereignty and IP-protection requirements. A USPTO provisional patent application has been filed covering sample-size planning for model-guided experimental optimization.

Commercial economics are split between enterprise SaaS subscriptions to Reactosphere and project-based engagements with government agencies, research institutions, and commercial partners; pricing is quote-based and not publicly disclosed. Revenue diversification is limited at this stage: the company is almost entirely dependent on a small handful of named engagements, including the B.C. Track and Trace program with Aidos Innovations, RCMP and Canada Border Services Agency, the National Research Council of Canada's IRAP program, UBC research collaborations, and a Resilience Biosciences partnership for non-opioid therapeutics. The company has secured non-dilutive NRC IRAP funding and a $3.5 million private placement led by a single US institutional investor with Maxim Group LLC as placement agent, while pursuing inorganic expansion through a proposed $41.7 million all-stock acquisition of Quantum.IQ Technologies Inc., a Vancouver-based post-quantum cryptography company.

Name

Redwood AI

Legal name

Redwood AI Corp.

Website

https://redwoodai.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Redwood AI Corp. is a Vancouver-based AI company building Reactosphere, a proprietary generative AI platform that accelerates chemical synthesis, drug discovery, and hazardous chemical screening for pharmaceutical, defense, public safety, industrial, and academic clients.

Ownership category

akta.pro rank

Product category

AI-Powered Chemistry & Drug Discovery Software

NAICS

Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design Services (541512)

SIC

Services-Computer Programming Services (7371), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Engineering & Model Development Services (BPAEAHAF)

Keywords

• AI chemistry platform
• Drug discovery software
• Chemical synthesis AI
• Pharmaceutical R&D
• Hazardous chemical screening

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. SaaS Subscriptions: Software-as-a-service deployments of the Reactosphere platform offered to pharmaceutical, biotechnology, industrial, and government organizations on a subscription basis
2. Project-Based Engagements: Strategic collaborations and project-based engagements with government agencies, research institutions, and commercial partners for specific applications of the AI platform

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Redwood AI develops and sells Reactosphere, a proprietary AI-powered chemistry synthesis platform that combines generative foundation models with deep chemistry expertise. The platform supports synthesis planning, reaction optimization, molecular design, and chemical procurement intelligence for pharmaceutical, biotechnology, defense, government, and industrial chemical clients. It enables users to design, refine, and scale complex compounds across the full development lifecycle from early-stage research through manufacturing.

Product overview

Redwood AI offers Reactosphere, a unified AI-powered chemistry platform that combines proprietary generative foundation models with deep chemistry expertise. The platform operates across the full development lifecycle from early-stage discovery through manufacturing scale-up. Core capabilities include synthesis planning, reaction optimization, molecular design, and chemical procurement intelligence. The platform is modular, consisting of the Reactosphere core system with integrated modules including the Optimization Module (Bayesian optimization and experimental planning), Chemical Risk Assessment Module (safety screening), Chemical Pricing and Availability System (vendor intelligence across 90+ vendors), and Q-SAFE (quantum-enhanced hazardous chemical classification). The platform is designed for pharmaceutical, defense, public safety, and industrial applications, with support for air-gapped and CPU-based deployments.

Differentiator

Problem solved

Functional benefit

Products and services

• Reactosphere AI-powered chemical synthesis platform supporting synthesis planning, reaction optimization, and molecular design. Combines proprietary generative foundation models with deep chemistry expertise to help teams design, refine, and scale complex compounds across the full development lifecycle from early-stage research through manufacturing. Built for pharmaceutical, biotechnology, defense, government, and industrial chemical clients.
• Q-SAFE Quantum-enhanced optimization technology for hazardous chemical risk classification. Uses AI and quantum methods to improve chemical screening for defense, security, and emergency response applications, targeting explosive, toxic, or dangerous substance detection.

Quantifiable outcome

• 425% increase in chemical reaction training examples (from 4 million to 21 million+)
• +1 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Quantum.IQ Technologies Inc.coreStrategic or Co-development Partner · 26 June 2026Definitive agreement to acquire all outstanding shares of Quantum.IQ, a Vancouver-based AI-driven quantum cybersecurity company developing post-quantum cryptography software. Deal valued at approximately $41.7 million (14,033,558 shares at $2.98), with milestone-based consideration up to additional 7 million shares upon achievement of revenue targets. Subject to CSE approval.
• University of Global Health Equity (Rwanda)minorStrategic or Co-development Partner · 11 June 2026Non-binding LOI to explore development of regional pathogen tracking and AI-enabled outbreak intelligence initiative focused on strengthening preparedness for emerging infectious diseases across Central and East Africa, initially targeting Rwanda and DRC.
• Resilience Biosciences Inc.minorStrategic or Co-development Partner · 22 May 2026Collaboration to advance AI-assisted small-molecule drug development, allowing Resilience to use Redwood's AI platform to explore new drug-like molecules efficiently, with focus on identifying chemical designs for non-opioid therapeutics for opioid withdrawal and related neurocognitive symptoms.
• University of British Columbia (Professor Jolene Reid)coreStrategic or Co-development Partner · 1 May 2026Research collaboration with UBC Professor Jolene Reid enhancing Reactosphere AI models, expanding evaluated chemical reaction universe from approximately 4 million to over 21 million training examples (425% increase). Supported by Mitacs Accelerate program funding. New models better interpret chemical reaction sequences rather than relying solely on pattern recognition.
• Aidos InnovationscoreStrategic or Co-development Partner · 17 April 2026Two-year collaboration with Aidos Innovations for the Track and Trace program, developing AI-powered analytical platform for detection and prediction of toxic opioids including fentanyl across Vancouver and Victoria in partnership with RCMP, Victoria Police Department, and Canada Border Services Agency. Redwood provides AI-powered analytical capabilities while Aidos leads the integrated platform combining advanced chemistry, AI, and operational intelligence.
• University of British Columbia (Brent Page Lab)coreStrategic or Co-development Partner · 1 April 2026Collaborative research project titled 'Novel Therapeutics for Neurodegeneration - Targeting NUDT5 in Alzheimer's Disease' applying Redwood's computational platform to generate and evaluate virtual compound libraries for synthesis and testing by the academic lab, aiming to identify novel drug candidates for Alzheimer's disease.
• National Research Council of Canada (NRC IRAP)coreStrategic or Co-development PartnerRedwood AI Operations Inc. approved to receive advisory services and funding of up to C$240,000 from NRC IRAP Defence Industry Assist program for Q-SAFE project developing quantum-enhanced optimization for hazardous chemical risk classification with applications for defense, security, and emergency response environments.
• Canadian Government & Law Enforcement AgenciescoreStrategic or Co-development PartnerCore technology contributor to British Columbia's Track and Trace initiative, a landmark AI-powered pilot program to disrupt illicit drug supply, working alongside RCMP, Victoria Police Department, Canada Border Services Agency, and 14 other law enforcement agencies. Also collaborated with B.C. Ministries of Public Safety and Health.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Insilico Medicine: AI-first drug discovery company using generative models and predictive chemistry platforms for small-molecule design — closely aligned with Redwood's generative foundation model approach to chemistry and pharmaceutical customer segment.
• Atomwise: AI-driven small-molecule drug discovery company using structure-based deep learning models for hit identification and optimization — comparable generative/predictive AI approach to chemistry with pharma and academic collaborators.
• Schrödinger, Inc. Public computational chemistry and molecular simulation platform used across pharma and materials R&D for synthesis planning, reaction prediction, and molecular design — directly overlapping with Reactosphere's core AI chemistry capabilities and target pharmaceutical customer base.
• Exscientia: AI-driven precision medicine and small-molecule drug design company using its own platform to accelerate discovery — directly comparable AI-for-chemistry platform with pharma partnerships and similar customer use cases around synthesis planning and reaction optimization.
• XtalPi: AI+robotics drug discovery company combining quantum physics, AI, and automated labs for small-molecule design and synthesis — overlaps with Redwood on AI-driven synthesis planning and pharmaceutical customer base.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining proprietary biological data generation with machine learning models — comparable to Redwood's generative AI approach for small-molecule discovery, though operating at much greater scale and capital intensity.

Broad incumbents

• Citrine Informatics: AI platform for materials and chemicals R&D serving industrial chemical customers with data-driven optimization — broader incumbent covering adjacent chemistry AI use cases beyond drug discovery.
• AbCellera Biologics: Public Canadian AI-driven biotech platform with broader antibody and small-molecule capabilities — comparable Canadian public-market profile and AI-for-discovery positioning.

Emerging players

• Iambic (formerly Entos): AI-native drug discovery platform using proprietary foundation models for generative chemistry — smaller-scale emerging player in the same AI-for-chemistry category as Redwood.
• Cradle Bio: AI platform for protein and biologics design with growing chemistry capabilities — adjacent emerging AI R&D platform competing for similar pharma R&D budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redwood AI